Volitionrx (VNRX) president Reynolds buys $56,100 in shares

VolitionRX LTD (NASDAQ:VNRX) President and CEO Cameron John Reynolds reported purchasing 110,000 shares of common stock at a price of $0.51 on October 14, 2025. The total value of the purchase was $56,100.

According to a Form 4 filing with the Securities and Exchange Commission, Reynolds also acquired 110,000 warrants (right to buy) at $0.01. Following the transaction, Reynolds directly owns 2,534,847 shares of VolitionRX LTD. He also indirectly owns 1,007,718 shares through Concord International, Inc. and 34,076 shares through his spouse. Track insider trading patterns and access comprehensive financial analysis with InvestingPro, which offers 10 additional key insights about VNRX’s current market position.

In other recent news, VolitionRx Limited announced the pricing of an underwritten public offering intended to raise approximately $6 million before expenses. The company is offering 11,550,000 shares of common stock and warrants priced at $0.52 each, with warrants exercisable at $0.60 per share. The proceeds from this offering are earmarked for research, product development, clinical studies, commercialization efforts, working capital, and potential strategic acquisitions. Newbridge Securities Corporation is acting as the sole book-running manager for this transaction. Additionally, the company has granted Newbridge a 30-day option to purchase up to an additional 15% of the shares and warrants offered. In related developments, H.C. Wainwright has maintained its Buy rating and $2.50 price target on VolitionRx following a co-marketing agreement with Hologic Diagenode. Meanwhile, Benchmark has reiterated its Hold rating on the company, though it did not specify a price target.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.